Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing FDA warnings, patent cliffs, or controlled-substance quotas in ANI Pharmaceuticals鈥� disclosures can feel like decoding another language. Each annual report blends clinical trial data, DEA quota details, and manufacturing risk factors that easily surpass 200 pages. If you have ever searched for 鈥淎NI Pharmaceuticals insider trading Form 4 transactions鈥� or tried to locate one footnote on steroid revenue, you know the challenge.
Stock Titan turns those challenges into clarity. Our platform delivers AI-powered summaries the moment an ANI Pharmaceuticals quarterly earnings report 10-Q filing or 8-K hits EDGAR, highlighting revenue by therapeutic class, fresh FDA correspondence, and supply-chain updates. Need real-time alerts? We surface ANI Pharmaceuticals Form 4 insider transactions real-time so you can monitor executive buys and sells minutes after they post. From the ANI Pharmaceuticals annual report 10-K simplified to every ANI Pharmaceuticals 8-K material events explained, you receive concise language, key metrics, and cross-linked definitions鈥攏o accounting degree required.
Below you will find every filing type鈥�10-K, 10-Q, 8-K, S-8, DEF 14A鈥攅ach paired with an AI snapshot that answers the questions investors actually ask: cash flows by product line, R&D spend on rare-disease assets, or how 鈥淎NI Pharmaceuticals proxy statement executive compensation鈥� aligns with pipeline milestones. Use our tools to:
- Run an 鈥淎NI Pharmaceuticals earnings report filing analysis鈥� in seconds
- Track 鈥淎NI Pharmaceuticals executive stock transactions Form 4鈥� before market open
- Master 鈥渦nderstanding ANI Pharmaceuticals SEC documents with AI鈥� without sifting through PDFs
Whether you are hunting for segment profitability or compliance triggers, Stock Titan delivers ANI Pharmaceuticals SEC filings explained simply鈥攕o you focus on decisions, not document digging.
ANIP Q2-25 revenue jumped 53% YoY to $211.4 m, propelled by Cortrophin Gel (+66% to $81.6 m) and the first full quarter of ILUVIEN/YUTIQ sales ($22.3 m) acquired with Alimera. Generics grew 22% to $90.3 m.
Gross margin widened to 64.7% (58.2% LY) while SG&A climbed 55% on integration and commercial scale-up. Operating income rose to $13.9 m (6.6% margin) from $5.2 m; net income swung to $8.5 m, delivering diluted EPS of $0.36 versus a $0.14 loss. Six-month revenue is $408.5 m (+48%) with EPS of $1.05.
Cash reached $217.8 m as operating cash flow tripled to $110.8 m. Total debt remains high at $621.6 m (incl. $306.9 m converts), leaving net debt of 鈮�$404 m and leverage near 2.9脳 LTM sales. Intangible assets of $520 m and goodwill of $60.5 m reflect the Alimera deal; contingent consideration stands at $18.6 m.
Management stresses ongoing rare-disease momentum, manufacturing synergies and expanded market reach, but notes risks around debt covenants, rising rebate liabilities and Alimera integration.
FAQ
What is the current stock price of Ani Pharmaceutic (ANIP)?
What is the market cap of Ani Pharmaceutic (ANIP)?
